Your browser doesn't support javascript.
loading
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil.
Botelho, Carlos Henrique; Estevez-Diz, Maria Del Pilar; Campolina, Alessandro Gonçalves.
Afiliação
  • Botelho CH; Department of Radiology and Oncology, Cancer Institute of the State of Sao Paulo/Faculty of Medicine at the University of Sao Paulo, Sao Paulo, Brazil.
  • Estevez-Diz MDP; Department of Radiology and Oncology, Cancer Institute of the State of Sao Paulo/Faculty of Medicine at the University of Sao Paulo, Sao Paulo, Brazil.
  • Campolina AG; Center for Translational Research in Oncology, Cancer Institute of the State of Sao Paulo/Faculty of Medicine of the University of Sao Paulo, São Paulo, Brazil.
Expert Rev Pharmacoecon Outcomes Res ; 22(1): 63-72, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34319216
BACKGROUND: Adjuvant chemotherapy with trastuzumab for HER2 positive breast cancers has brought considerable benefits to disease-free survival and overall survival. OBJECTIVE: To conduct a cost-effectiveness analysis of the treatment of patients with early and locally advanced HER2 positive breast cancer, within the scope of the Brazilian public health system, comparing adjuvant chemotherapy with and without trastuzumab, for 1 year of treatment. METHODS: A 4-state Markov model was developed to estimate strategy costs and outcomes. RESULTS: Based on the proposed model, we verified an incremental benefit of trastuzumab therapy compared to treatment without trastuzumab with 0.84 quality-adjusted life years (QALY) and 1.16 life years gained (LYG). The use of adjuvant chemotherapy with trastuzumab has an ICER of US$19,599.26 for each quality-adjusted life year and US$14,180.68 for each life year gained in relation to chemotherapy without trastuzumab. CONCLUSION: In Brazil, adjuvant chemotherapy with trastuzumab may be considered cost-effective only if a cost-effectiveness threshold is stipulated with the value starting at three times the Brazilian GDP per capita for QALY or two times the Brazilian GDP per capita for LYG, from health system perspective.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Limite: Female / Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Imunológicos Tipo de estudo: Health_economic_evaluation Aspecto: Patient_preference Limite: Female / Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Expert Rev Pharmacoecon Outcomes Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido